Research programme: Parkinson's disease therapeutics - Alnylam Pharmaceuticals/Mayo Clinic

Drug Profile

Research programme: Parkinson's disease therapeutics - Alnylam Pharmaceuticals/Mayo Clinic

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Mayo Clinic
  • Class Small interfering RNA
  • Mechanism of Action Alpha-synuclein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Intracerebral, Injection)
  • 05 Nov 2008 Interim pharmacodynamics and safety data from a preclinical trial in a mouse model of Parkinson's disease released by Alnylam Pharmaceuticals
  • 05 Jan 2008 Alnylam Pharmaceuticals, the Mayo Clinic, and the Parkinson's Institute and Clinical Center receive a grant from the Michael J. Fox Foundation for development of therapeutics targeting alpha-synuclein for Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top